###begin article-title 0
Beneficial Effect of Low Ethanol Intake on the Cardiovascular System: Possible Biochemical Mechanisms
###end article-title 0
###begin p 1
###xml 882 883 882 883 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
Low ethanol intake is known to have a beneficial effect on cardiovascular disease. In cardiovascular disease, insulin resistance leads to altered glucose and lipid metabolism resulting in an increased production of aldehydes, including methylglyoxal. Aldehydes react non-enzymatically with sulfhydryl and amino groups of proteins forming advanced glycation end products (AGEs), altering protein structure and function. These alterations cause endothelial dysfunction with increased cytosolic free calcium, peripheral vascular resistance, and blood pressure. AGEs produce atherogenic effects including oxidative stress, platelet adhesion, inflammation, smooth muscle cell proliferation and modification of lipoproteins. Low ethanol intake attenuates hypertension and atherosclerosis but the mechanism of this effect is not clear. Ethanol at low concentrations is metabolized by low Km alcohol dehydrogenase and aldehyde dehydrogenase, both reactions resulting in the production of reduced nicotinamide adenine dinucleotide (NADH). This creates a reductive environment, decreasing oxidative stress and secondary production of aldehydes through lipid peroxidation. NADH may also increase the tissue levels of the antioxidants cysteine and glutathione, which bind aldehydes and stimulate methylglyoxal catabolism. Low ethanol improves insulin resistance, increases high-density lipoprotein and stimulates activity of the antioxidant enzyme, paraoxonase. In conclusion, we suggest that chronic low ethanol intake confers its beneficial effect mainly through its ability to increase antioxidant capacity and lower AGEs.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 277 286 277 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b144">WHO 2003a</xref>
###xml 450 469 450 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b96">Reynolds et al 2003</xref>
###xml 471 488 471 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">Corrao et al 2004</xref>
###xml 637 655 637 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">Camargo et al 1997</xref>
###xml 657 673 657 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b84">Okubo et al 2001</xref>
###xml 675 692 675 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">Corrao et al 2004</xref>
###xml 694 704 694 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b90">Piano 2005</xref>
Ethanol intake is a common lifestyle factor found across many cultures and geographic regions. Since cardiovascular disease is also found ubiquitously and accounts for more than 16 million deaths per year worldwide, it is essential to understand how they relate to each other (WHO 2003a). Various epidemiological and controlled clinical studies have investigated the effects of varying levels and patterns of ethanol intake on cardiovascular health (Reynolds et al 2003; Corrao et al 2004). In contrast to high ethanol intake which is detrimental to cardiovascular health, chronic low ethanol has been shown to have a beneficial effect (Camargo et al 1997; Okubo et al 2001; Corrao et al 2004; Piano 2005). Understanding the biological mechanism of this beneficial effect will aid in identifying potential preventative or therapeutic agents. In this review, we discuss the factors involved in the development and progression of cardiovascular disease and the possible biochemical mechanisms by which low ethanol counters these factors to prevent or attenuate this disease.
###end p 3
###begin title 4
Cardiovascular disease
###end title 4
###begin p 5
###xml 175 184 175 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b145">WHO 2003b</xref>
###xml 554 566 554 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b95">Resnick 1993</xref>
###xml 568 589 568 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b85">Oshima and Young 1995</xref>
###xml 591 608 591 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b118">Taddei et al 2003</xref>
###xml 610 631 610 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b92">Portaluppi et al 2004</xref>
###xml 1036 1045 1036 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b145">WHO 2003b</xref>
###xml 109 115 <span type="species:ncbi:9606">people</span>
Cardiovascular disease includes atherosclerosis and hypertension. Hypertension affects more than 600 million people worldwide and results in 13% of the total deaths globally (WHO 2003b). Approximately 90% of all hypertension is classified as "essential" meaning that the cause is not known. Essential hypertension involves endothelial dysfunction with alterations in nitric oxide (NO) bioavailability and calcium handling, smooth muscle cell proliferation, thickening of the vessel walls, and increased peripheral vascular resistance and blood pressure (Resnick 1993; Oshima and Young 1995; Taddei et al 2003; Portaluppi et al 2004). Risk factors for hypertension include family history, diabetes, obesity, smoking, excessive alcohol intake, and a diet high in salt and/or low in antioxidant nutrients. Most of these risk factors are modifiable through lifestyle changes such as participating in moderate physical activity and eating a well-balanced diet. Healthy lifestyle choices also include not smoking and limiting alcohol intake (WHO 2003b). Individuals with hypertension are at increased risk for atherosclerotic diseases such as stroke, and heart and kidney disease.
###end p 5
###begin p 6
###xml 223 232 223 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b144">WHO 2003a</xref>
###xml 302 311 302 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b99">Ross 1999</xref>
###xml 953 975 953 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">Chakarvarti et al 1991</xref>
###xml 977 1003 977 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b142">Witztum and Steinberg 1991</xref>
###xml 1005 1024 1005 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b87">Palinski et al 1995</xref>
###xml 1026 1035 1026 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b99">Ross 1999</xref>
###xml 1037 1057 1037 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b110">Sima and Stancu 2002</xref>
###xml 1059 1071 1059 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b55">Hansson 2005</xref>
###xml 1219 1235 1219 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b120">Tegos et al 2001</xref>
###xml 1237 1249 1237 1249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b55">Hansson 2005</xref>
###xml 1486 1502 1486 1502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b120">Tegos et al 2001</xref>
###xml 1854 1882 1854 1882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">Chobanian and Alexander 1996</xref>
###xml 2008 2019 2008 2019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b83">Neutel 2000</xref>
###xml 2135 2144 2135 2144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b144">WHO 2003a</xref>
###xml 2146 2151 2146 2151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b145">2003b</xref>
###xml 2286 2310 2286 2310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b89">Pepine and Handberg 2001</xref>
Atherosclerosis is a leading cause of death in the world. Heart disease and stroke are the two leading causes of death in adults in developed countries and are responsible for a third of all deaths in developing countries (WHO 2003a). Atherosclerosis is an inflammatory condition of the blood vessels (Ross 1999). Damage to, or activation of, the endothelium promotes entry of modified low-density lipoprotein (LDL) into the intima, a process enhanced by an elevation in circulating levels of LDL. Alteration in endothelium also increases the expression of adhesion molecules on the cell surface resulting in recruitment of monocytes and platelet adhesion. The monocytes transmigrate to the sub-endothelial space where they differentiate into macrophages. Modified LDL is scavenged by macrophages in the interstitial space transforming over time into foam cells. Accumulation of foam cells and other cellular debris evolve into atherosclerotic plaques (Chakarvarti et al 1991; Witztum and Steinberg 1991; Palinski et al 1995; Ross 1999; Sima and Stancu 2002; Hansson 2005). Although atherosclerotic lesions generally occur at junctions of large- and medium-size vessels, they may also arise throughout the vasculature (Tegos et al 2001; Hansson 2005). Through stenosis or embolytic occlusion, lesions within the coronary, cerebral, peripheral or renal vessels result in the clinical manifestations of angina, myocardial infarction, stroke, peripheral arterial disease or renal failure (Tegos et al 2001). Atherosclerosis also involves increased smooth muscle cell migration and proliferation. Stiffening of the vessel walls may hinder elasticity exacerbating hypertension. Hypertension is considered a risk factor for atherosclerosis, as increased blood pressure itself can contribute to vascular injury, making vessels more susceptible to inflammation (Chobanian and Alexander 1996). However, studies show that lowering blood pressure alone does not completely eliminate the risk of cardiovascular disease (Neutel 2000). Other risk factors include smoking, diabetes mellitus, obesity, dyslipidemias, and a diet high in saturated fat (WHO 2003a, 2003b). Hypertension and atherosclerosis share similar risk factors and both are characterized by modified vascular structure and function (Pepine and Handberg 2001). These cardiovascular conditions are also linked by another common feature, insulin resistance.
###end p 6
###begin title 7
Etiological factors of cardiovascular disease
###end title 7
###begin title 8
Insulin resistance
###end title 8
###begin p 9
###xml 92 100 92 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
###xml 342 363 342 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">Ferrannini et al 1987</xref>
###xml 561 582 561 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">Ferrannini et al 1987</xref>
###xml 584 599 584 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b100">Saad et al 2004</xref>
###xml 601 621 601 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b138">Vlasakova et al 2004</xref>
###xml 720 741 720 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">Ferrannini et al 1987</xref>
###xml 743 764 743 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">Flack and Sowers 1991</xref>
###xml 843 871 843 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">DeFronzo and Ferrannini 1991</xref>
###xml 873 890 873 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b58">Howard et al 1996</xref>
###xml 892 912 892 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b109">Shinozaki et al 1996</xref>
###xml 914 925 914 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b94">Reaven 2003</xref>
###xml 1046 1057 1046 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b94">Reaven 2003</xref>
###xml 1059 1074 1059 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b68">Liao et al 2004</xref>
###xml 1324 1352 1324 1352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">DeFronzo and Ferrannini 1991</xref>
###xml 447 453 <span type="species:ncbi:9606">Humans</span>
###xml 814 820 <span type="species:ncbi:9606">humans</span>
We suggest that the key etiological factor in cardiovascular disease is insulin resistance (Figure 1). Insulin resistance is characterized by an inadequate glucose uptake in peripheral tissues at a given concentration of plasma insulin. It involves an impairment of the nonoxidative (glycolytic) pathways of intracellular glucose metabolism (Ferrannini et al 1987). Insulin resistance has been well documented in hypertension and atherosclerosis. Humans with essential hypertension and normotensive offspring of essential hypertensives have insulin resistance (Ferrannini et al 1987; Saad et al 2004; Vlasakova et al 2004). Abnormalities in glucose metabolism exist in up to 80% of subjects with essential hypertension (Ferrannini et al 1987; Flack and Sowers 1991). Insulin resistance has also been documented in humans with atherosclerosis (DeFronzo and Ferrannini 1991; Howard et al 1996; Shinozaki et al 1996; Reaven 2003). It has been suggested that hypertensives who are insulin resistant are at increased risk for atherosclerotic disease (Reaven 2003; Liao et al 2004). In metabolic syndrome, also known as syndrome X or insulin resistance syndrome, primary insulin resistance is linked to a group of co-existing conditions including hypertension, dyslipidemias, diabetes, and atherosclerotic cardiovascular disease (DeFronzo and Ferrannini 1991).
###end p 9
###begin p 10
Mechanism of cardiovascular disease. In insulin resistant state, excess aldehydes formed due to altered glucose/lipid metabolism react with proteins to form advanced glycation end products (AGEs). AGEs alter the functions of cellular proteins including vascular ion channels, and metabolic and antioxidant enzymes, with oxidative stress leading to hypertension and atherosclerosis.
###end p 10
###begin title 11
Aldehydes
###end title 11
###begin p 12
###xml 452 472 452 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">Alexander et al 1988</xref>
###xml 772 782 772 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b74">Mayes 1983</xref>
###xml 784 799 784 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b123">Thornalley 1993</xref>
###xml 801 823 801 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">Beisswenger et al 2003</xref>
###xml 938 955 938 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b80">Morgan et al 2002</xref>
###xml 1114 1130 1114 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">Chang et al 2002</xref>
###xml 1328 1342 1328 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49">Fuh et al 1987</xref>
###xml 1344 1359 1344 1359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b68">Liao et al 2004</xref>
###xml 1510 1521 1510 1521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">Dargel 1992</xref>
Under normal physiological conditions, glucose is metabolized via the glycolytic pathway to glyceraldehyde-3-phosphate (G3P) which is converted to 1,3-diphosphoglycerate by the enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH), with further metabolism to pyruvate. Any factor which affects GAPDH, whether through inhibition or upregulation, has an impact on the rate of glucose metabolism. It has been shown that GAPDH is upregulated by insulin (Alexander et al 1988). In insulin resistant states, altered insulin function may down regulate GAPDH, slowing glucose metabolism through the glycolytic pathway, thus increasing metabolism via the polyol pathway. This may result in a build-up of G3P leading to an increase in the highly reactive aldehyde, methylglyoxal (Mayes 1983; Thornalley 1993; Beisswenger et al 2003). Methylglyoxal itself has been shown to inhibit GAPDH, resulting in further abnormalities in glucose metabolism (Morgan et al 2002). Methylglyoxal also induces aldose reductase which is known to stimulate flux of glucose through the polyol pathway with further formation of methylglyoxal (Chang et al 2002). An excess of dietary sugar or fat, or both, typical of western diets, may overload these pathways and exacerbate this altered metabolism. Insulin resistance is also associated with dyslipidemia (Fuh et al 1987; Liao et al 2004); elevated LDL without the mitigating antioxidant effect of high high-density lipoprotein (HDL), may contribute to an increase in reactive aldehydes (Dargel 1992).
###end p 12
###begin title 13
Advanced glycation end products
###end title 13
###begin p 14
###xml 165 166 165 166 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 243 266 243 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b103">Schauenstein et al 1977</xref>
###xml 268 290 268 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b124">Thorpe and Baynes 2003</xref>
###xml 292 313 292 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b122">Thornalley et al 2003</xref>
###xml 393 410 393 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b80">Morgan et al 2002</xref>
###xml 412 430 412 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b82">Nagaraj et al 2002</xref>
###xml 432 454 432 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b61">Karachalias et al 2003</xref>
###xml 615 633 615 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b104">Schmidt et al 2001</xref>
###xml 635 653 635 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b141">Wautier et al 2001</xref>
###xml 655 674 655 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b57">Horiuchi et al 2003</xref>
###xml 873 896 873 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b103">Schauenstein et al 1977</xref>
###xml 1018 1037 1018 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b63">Kirstein et al 1992</xref>
###xml 1080 1098 1080 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b131">Vasdev et al 2000a</xref>
###xml 1100 1105 1100 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b132">2000b</xref>
###xml 1107 1126 1107 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b78">Mizutani et al 2002</xref>
###xml 1128 1147 1128 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">Alderson et al 2003</xref>
###xml 1149 1167 1149 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">Bidasee et al 2003</xref>
###xml 1169 1191 1169 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b61">Karachalias et al 2003</xref>
###xml 1193 1209 1193 1209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b115">Stitt et al 2004</xref>
###xml 1211 1228 1211 1228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b133">Vasdev et al 2005</xref>
###xml 1382 1409 1382 1409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b119">Takeuchi and Yamagishi 2004</xref>
###xml 1650 1669 1650 1669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Anderson et al 1999</xref>
###xml 1671 1685 1671 1685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b86">Oya et al 1999</xref>
###xml 1687 1709 1687 1709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">Baynes and Thorpe 2000</xref>
###xml 1711 1727 1711 1727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b81">Nagai et al 2002</xref>
###xml 1729 1748 1729 1748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">Alderson et al 2003</xref>
###xml 1750 1765 1750 1765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b139">Wang et al 2004</xref>
Advanced glycation end products (AGEs) are formed when aldehydes (eg, methylglyoxal, glyoxal, glucose) react nonenzymatically with free sulfhydryl (SH) and amino (NH2) groups of amino acids including cysteine, arginine or lysine, of proteins (Schauenstein et al 1977; Thorpe and Baynes 2003; Thornalley et al 2003). This direct modification of protein structure results in functional changes (Morgan et al 2002; Nagaraj et al 2002; Karachalias et al 2003). AGE-modified protein has also been shown to stimulate receptors of AGEs (RAGEs) and various scavenger receptors to influence protein function and expression (Schmidt et al 2001; Wautier et al 2001; Horiuchi et al 2003). Normally, methylglyoxal is formed but kept at a low level through catabolism via the glutathione-dependent glyoxalase enzyme system or by binding to cysteine and being excreted in bile and urine (Schauenstein et al 1977). It has been suggested that AGEs formed in low concentrations contribute to the regulation of normal tissue remodeling (Kirstein et al 1992) but when found in excess are pathogenic (Vasdev et al 2000a, 2000b; Mizutani et al 2002; Alderson et al 2003; Bidasee et al 2003; Karachalias et al 2003; Stitt et al 2004; Vasdev et al 2005). It has also been proposed that certain AGEs have normal biological functions whereas others referred to as toxic AGEs, play a pathophysiological role (Takeuchi and Yamagishi 2004). Whatever the case, several specific AGEs including carboxymethyl-lysine, carboxyethyl-lysine, argpyrimidine, and glycoaldehyde-pyridine, have been identified, and have been implicated in the pathology of hypertension and atherosclerosis (Anderson et al 1999; Oya et al 1999; Baynes and Thorpe 2000; Nagai et al 2002; Alderson et al 2003; Wang et al 2004).
###end p 14
###begin title 15
Causative role of advanced glycation end products in cardiovascular disease
###end title 15
###begin p 16
###xml 284 292 284 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 535 552 535 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b129">Vasdev et al 1998</xref>
###xml 684 702 684 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b131">Vasdev et al 2000a</xref>
###xml 704 709 704 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b132">2000b</xref>
###xml 711 731 711 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b146">Wu and Juurlink 2002</xref>
###xml 733 751 733 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b76">Midaoui et al 2003</xref>
###xml 753 768 753 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b139">Wang et al 2004</xref>
###xml 945 961 945 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">Cooke et al 2003</xref>
###xml 1113 1125 1113 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">Aronson 2003</xref>
###xml 1320 1340 1320 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64">Kislinger et al 2001</xref>
###xml 1342 1363 1342 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">Degenhardt et al 2002</xref>
###xml 1365 1383 1365 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b82">Nagaraj et al 2002</xref>
###xml 1385 1409 1385 1409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">Babaei-Jadidi et al 2003</xref>
###xml 1411 1433 1411 1433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b61">Karachalias et al 2003</xref>
###xml 1435 1449 1435 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">Alt et al 2004</xref>
###xml 1451 1467 1451 1467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b115">Stitt et al 2004</xref>
###xml 1673 1691 1673 1691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b131">Vasdev et al 2000a</xref>
###xml 1693 1698 1693 1698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b132">2000b</xref>
###xml 1700 1704 1700 1704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b134">2002</xref>
###xml 1706 1726 1706 1726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64">Kislinger et al 2001</xref>
###xml 1728 1749 1728 1749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">Degenhardt et al 2002</xref>
###xml 1751 1770 1751 1770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b78">Mizutani et al 2002</xref>
###xml 1772 1791 1772 1791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">Alderson et al 2003</xref>
###xml 1793 1817 1793 1817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">Babaei-Jadidi et al 2003</xref>
###xml 1819 1837 1819 1837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b76">Midaoui et al 2003</xref>
###xml 1839 1859 1839 1859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b101">Sakaguchi et al 2003</xref>
###xml 1861 1882 1861 1882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b112">Smit and Lutgers 2004</xref>
###xml 1884 1900 1884 1900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b115">Stitt et al 2004</xref>
###xml 483 487 <span type="species:ncbi:10116">rats</span>
###xml 636 640 <span type="species:ncbi:10116">rats</span>
###xml 642 645 <span type="species:ncbi:10116">SHR</span>
###xml 678 682 <span type="species:ncbi:10116">rats</span>
###xml 800 805 <span type="species:ncbi:9606">human</span>
It is known that AGEs act directly or via receptors to alter the function of cellular proteins including calcium channels, metabolic and antioxidant enzymes, receptors and structural proteins leading to endothelial dysfunction, inflammatory responses, and increased oxidative stress (Figure 2). Thus, it is becoming increasingly clear that AGEs play a major causative role in hypertension and atherosclerosis. We have shown that methylglyoxal given in the diet to Wistar-Kyoto (WKY) rats increased tissue AGEs and caused hypertension (Vasdev et al 1998). Levels of tissue methylglyoxal and AGEs are higher in spontaneously hypertensive rats (SHR) and sugar-induced hypertensive rats (Vasdev et al 2000a, 2000b; Wu and Juurlink 2002; Midaoui et al 2003; Wang et al 2004). Although research on AGEs in human essential hypertension is scant, in preeclampsia, a hypertensive condition of pregnancy, RAGE expression was increased in vascular tissue (Cooke et al 2003). AGE-mediated crosslinks in collagen and elastin, also contribute to arterial stiffening, hindering vessel elasticity, and exacerbating hypertension (Aronson 2003). There is strong evidence in diabetes, another insulin resistant state, that AGEs are responsible for cellular protein modifications which contribute to diabetic atherosclerotic complications (Kislinger et al 2001; Degenhardt et al 2002; Nagaraj et al 2002; Babaei-Jadidi et al 2003; Karachalias et al 2003; Alt et al 2004; Stitt et al 2004). Evidence supporting the concept that AGEs are involved in the etiology of cardiovascular disease shows that compounds which lower AGEs also lower blood pressure and attenuate atherosclerotic conditions (Vasdev et al 2000a, 2000b, 2002; Kislinger et al 2001; Degenhardt et al 2002; Mizutani et al 2002; Alderson et al 2003; Babaei-Jadidi et al 2003; Midaoui et al 2003; Sakaguchi et al 2003; Smit and Lutgers 2004; Stitt et al 2004).
###end p 16
###begin p 17
Atherosclerotic and hypertensive effects of advanced glycation end products (AGEs) on blood vessels. AGEs act directly and via receptors of AGEs (RAGES) to alter the function of cellular proteins including calcium channels, endothelial nitric oxide synthase (eNOS), antioxidant enzyme superoxide dismutase (SOD) resulting in a decrease in NO and an increase of reactive oxygen species (ROS), cytokines, imflammation, platelet aggregation and vascular smooth muscle cell (VSMC) proliferation. AGEs and ROS also modify low density lipoprotein (LDL) increasing uptake by macrophages contributing to the formation of plaque. These alterations lead to hypertension and atherosclerosis.
###end p 17
###begin title 18
Vascular dysfunction
###end title 18
###begin p 19
###xml 438 455 438 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b118">Taddei et al 2003</xref>
###xml 543 560 543 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b118">Taddei et al 2003</xref>
###xml 562 582 562 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b108">Shinozaki et al 2004</xref>
Maintaining normal endothelial function is essential to blood pressure homeostasis and vessel integrity. One of the major factors involved in regulation of endothelial function is NO. Endothelium derived NO is not only a potent vasodilator but it inhibits platelet aggregation, vascular smooth muscle cell (VSMC) proliferation and intimal migration, and monocyte adhesion, thus regulating blood pressure and protecting vascular function (Taddei et al 2003). Abnormalities in NO have been demonstrated in both hypertension and atherosclerosis (Taddei et al 2003; Shinozaki et al 2004).
###end p 19
###begin p 20
###xml 176 193 176 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b118">Taddei et al 2003</xref>
###xml 286 303 286 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b107">Shamsi et al 1998</xref>
###xml 305 319 305 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b86">Oya et al 1999</xref>
###xml 321 342 321 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b122">Thornalley et al 2003</xref>
###xml 385 406 385 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">Degenhardt et al 2002</xref>
###xml 495 510 495 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">Chen et al 1994</xref>
###xml 575 593 575 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b136">Verbeke et al 2000</xref>
###xml 595 611 595 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b98">Rojas et al 2000</xref>
###xml 724 741 724 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b129">Vasdev et al 1998</xref>
###xml 837 855 837 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b127">Trovati et al 1997</xref>
###xml 857 872 857 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b60">Kahn et al 2000</xref>
###xml 967 983 967 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b106">Sechi et al 1996</xref>
###xml 985 1002 985 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b129">Vasdev et al 1998</xref>
###xml 1004 1008 1004 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b133">2005</xref>
###xml 1369 1391 1369 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b102">Scharfstein et al 1994</xref>
###xml 1393 1411 1393 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">Alencar et al 2003</xref>
###xml 1647 1669 1647 1669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43">Farkas and Menzel 1995</xref>
###xml 1671 1693 1671 1693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b124">Thorpe and Baynes 2003</xref>
###xml 672 676 <span type="species:ncbi:10116">rats</span>
The ability of vascular tissue to form adequate amounts of NO depends on the availability of its substrate, arginine, and the endothelial enzyme, nitric oxide synthase (eNOS) (Taddei et al 2003). Methylglyoxal reacts with arginine residues to form several AGEs including argpyrimidine (Shamsi et al 1998; Oya et al 1999; Thornalley et al 2003), which may limit substrate availability (Degenhardt et al 2002). eNOS is an SH-dependent enzyme with a cysteine residue identified at its active site (Chen et al 1994). AGEs have been shown to inhibit eNOS activity and expression (Verbeke et al 2000; Rojas et al 2000). We have shown that methylglyoxal given in the diet to WKY rats increased tissue AGEs and decreased plasma NO (Vasdev et al 1998). NO production is also regulated by insulin acting on specific receptors on the cell surface (Trovati et al 1997; Kahn et al 2000). In insulin resistant states, aldehydes may alter receptor function decreasing NO formation (Sechi et al 1996; Vasdev et al 1998, 2005). NO has a very short half life. Under physiological conditions, it has been shown to readily react with SH groups of plasma proteins forming biologically stable adducts (S-nitrosothiols) which represent a pool of available NO. Low molecular weight thiols such as cysteine and glutathione act as transfer agents for NO from these pools to NO's site of action (Scharfstein et al 1994; Alencar et al 2003). Since aldehydes also readily react with SH groups, this suggests a competitive role limiting both protein binding sites and transfer agent availability resulting in an increase in NO degradation and possible endothelial dysfunction (Farkas and Menzel 1995; Thorpe and Baynes 2003).
###end p 20
###begin p 21
###xml 74 97 74 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b103">Schauenstein et al 1977</xref>
###xml 99 115 99 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b148">Zaidi et al 1989</xref>
###xml 405 423 405 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">Bidasee et al 2003</xref>
###xml 483 504 483 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b105">Scivattaro et al 2000</xref>
###xml 707 724 707 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b129">Vasdev et al 1998</xref>
###xml 726 731 726 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b131">2000a</xref>
###xml 733 738 733 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b132">2000b</xref>
###xml 669 673 <span type="species:ncbi:10116">rats</span>
Vascular calcium channels are dependent on SH groups for normal function (Schauenstein et al 1977; Zaidi et al 1989) and their alteration can lead to increased cytosolic free calcium, abnormal contractile activity and increased peripheral vascular resistance. AGEs impair type 2 ryanodine receptor calcium release channels (calcium receptors which regulate cardiac contractility) during chronic diabetes (Bidasee et al 2003) and AGE-modified protein increases intracellular calcium (Scivattaro et al 2000). We have shown increased vascular AGEs and platelet cytosolic free calcium in SHRs, a genetic model of hypertension and in methylglyoxal- and fructose-treated WKY rats, dietary models of hypertension (Vasdev et al 1998, 2000a, 2000b).
###end p 21
###begin p 22
###xml 185 194 185 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">Ding 1996</xref>
###xml 352 372 352 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b53">Hangaishi et al 1998</xref>
###xml 518 533 518 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b140">Wang et al 2005</xref>
###xml 326 331 <span type="species:ncbi:9606">human</span>
Since calcium plays a key role in platelet activation, elevated intracellular free calcium may contribute to the enhanced platelet aggregation seen in hypertension and atherosclerosis (Ding 1996). AGEs may also contribute to platelet aggregation and thrombus formation. AGEs increased superoxide production and aggregation in human platelets in vitro (Hangaishi et al 1998). It has been suggested that AGEs stimulate externalization of phosphatidylserine which activates clotting factors leading to platelet adhesion (Wang et al 2005).
###end p 22
###begin title 23
Oxidative stress
###end title 23
###begin p 24
###xml 193 217 193 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b126">Touyz and Schiffrin 2004</xref>
###xml 418 433 418 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b62">Kaul et al 1993</xref>
###xml 464 465 464 465 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 556 573 556 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b80">Morgan et al 2002</xref>
###xml 575 595 575 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b146">Wu and Juurlink 2002</xref>
###xml 597 612 597 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b88">Park et al 2003</xref>
###xml 748 772 748 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">Brooks and Klamerth 1968</xref>
###xml 774 797 774 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b103">Schauenstein et al 1977</xref>
###xml 799 819 799 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">Benedetti et al 1980</xref>
###xml 821 842 821 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b121">Thornalley et al 1984</xref>
###xml 844 855 844 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">Dargel 1992</xref>
###xml 857 881 857 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b126">Touyz and Schiffrin 2004</xref>
###xml 1058 1080 1058 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">Baynes and Thorpe 2000</xref>
###xml 1082 1104 1082 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b124">Thorpe and Baynes 2003</xref>
###xml 1106 1122 1106 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b115">Stitt et al 2004</xref>
Under normal physiological conditions, reactive oxygen species (ROS) are produced in low concentrations and act as signaling molecules to regulate VSMC contraction-relaxation, and VSMC growth (Touyz and Schiffrin 2004). Oxidative stress occurs when ROS outweigh the body's antioxidant capacity. Oxidative stress is controlled in part by antioxidant enzymes, including glutathione peroxidase and glutathione reductase (Kaul et al 1993). These enzymes have SH and NH2 groups at their active sites and AGEs inhibit their activity increasing oxidative stress (Morgan et al 2002; Wu and Juurlink 2002; Park et al 2003). Excess ROS can lead to the secondary production of aldehydes such as malondialdehyde and hydroxynonenal, through lipid peroxidation (Brooks and Klamerth 1968; Schauenstein et al 1977; Benedetti et al 1980; Thornalley et al 1984; Dargel 1992; Touyz and Schiffrin 2004). These lipid-derived aldehydes have been shown to react with cysteine or lysine residues of proteins to form a type of AGE known as advanced lipoxidation end products (ALEs) (Baynes and Thorpe 2000; Thorpe and Baynes 2003; Stitt et al 2004).
###end p 24
###begin p 25
###xml 144 166 144 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">Chakravarti et al 1991</xref>
###xml 168 186 168 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b67">Kumar and Das 1993</xref>
###xml 188 216 188 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">Chobanian and Alexander 1996</xref>
###xml 218 241 218 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b116">Stocker and Keaney 2004</xref>
###xml 243 267 243 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b126">Touyz and Schiffrin 2004</xref>
###xml 669 678 669 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b99">Ross 1999</xref>
###xml 680 703 680 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b116">Stocker and Keaney 2004</xref>
###xml 705 717 705 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b55">Hansson 2005</xref>
There is strong evidence that oxidative stress contributes to the progression of essential hypertension and the development of atherosclerosis (Chakravarti et al 1991; Kumar and Das 1993; Chobanian and Alexander 1996; Stocker and Keaney 2004; Touyz and Schiffrin 2004). Oxidative modification of LDL increases uptake by macrophages via scavenger receptors (further discussed in dislipidemia section). This results in an increased production and accumulation of foam cells in the vascular intima leading to the formation of atherosclerotic lesions. Oxidized LDL also stimulates atherogenic processes including inflammation, platelet aggregation, and VSMC proliferation (Ross 1999; Stocker and Keaney 2004; Hansson 2005).
###end p 25
###begin p 26
###xml 121 141 121 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">Alp and Channon 2004</xref>
###xml 143 163 143 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b108">Shinozaki et al 2004</xref>
###xml 425 450 425 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">Beckman and Koppenol 1996</xref>
###xml 522 541 522 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Anderson et al 1999</xref>
###xml 543 564 543 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b105">Scivittaro et al 2000</xref>
###xml 566 584 566 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b141">Wautier et al 2001</xref>
###xml 586 605 586 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b78">Mizutani et al 2002</xref>
###xml 607 627 607 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b146">Wu and Jurrlink 2002</xref>
###xml 629 647 629 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b76">Midaoui et al 2003</xref>
###xml 649 664 649 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b143">Wong et al 2003</xref>
###xml 759 775 759 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">Chang et al 2005</xref>
Oxidative stress impairs endothelial function. ROS promote uncoupling of eNOS resulting in a decreased production of NO (Alp and Channon 2004; Shinozaki et al 2004). ROS also react directly with NO, forming peroxynitrite, also known as reactive nitrogen species. This not only limits NO bioavailability, but peroxynitrite and peroxynitrous acid are powerful and cyto-toxic oxidants which may cause damage to vascular tissue (Beckman and Koppenol 1996). Methylglyoxal and AGEs have been shown to increase oxidative stress (Anderson et al 1999; Scivittaro et al 2000; Wautier et al 2001; Mizutani et al 2002; Wu and Jurrlink 2002; Midaoui et al 2003; Wong et al 2003) and in VSMC in vitro induced significant generation of superoxide radical and peroxynitrite (Chang et al 2005).
###end p 26
###begin title 27
Dyslipidemia
###end title 27
###begin p 28
###xml 190 206 190 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b48">Fodor et al 2000</xref>
Dyslipidemia has long been associated with atherosclerosis, and controlling elevated cholesterol and abnormal lipoprotein ratios is a recognized preventative cardiovascular health strategy (Fodor et al 2000). It is well known that high levels of HDL offer protective cardiovascular effect, and that elevated LDL is associated with higher risk of cardiovascular disease.
###end p 28
###begin p 29
###xml 227 235 227 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 407 433 407 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b142">Witztum and Steinberg 1991</xref>
###xml 435 455 435 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b52">Haberland et al 1992</xref>
###xml 457 476 457 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b57">Horiuchi et al 2003</xref>
###xml 619 642 619 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b116">Stocker and Keaney 2004</xref>
###xml 805 831 805 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b142">Witztum and Steinberg 1991</xref>
###xml 833 849 833 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b72">Maggi et al 1993</xref>
However, the roles of these lipoproteins are complex and have not yet been fully elucidated. It has been proposed that in its native state LDL is not atherogenic but becomes so under conditions where its structure is modified (Figure 2). Alterations to lysine residues of apolipoprotein B of LDL result in a decreased binding by LDL receptors and an increased stimulation of macrophage scavenger receptors (Witztum and Steinberg 1991; Haberland et al 1992; Horiuchi et al 2003). Oxidatively modified LDL initiates atherogenic processes including inflammation, platelet aggregation and smooth muscle cell proliferation (Stocker and Keaney 2004). Oxidized LDL has been identified as a main component in atherosclerotic lesions, and hypertensive subjects exhibit an enhanced susceptibility to LDL oxidation (Witztum and Steinberg 1991; Maggi et al 1993).
###end p 29
###begin p 30
###xml 124 132 124 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 218 237 218 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b57">Horiuchi et al 2003</xref>
###xml 349 369 349 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b52">Haberland et al 1992</xref>
###xml 371 390 371 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b57">Horiuchi et al 2003</xref>
###xml 534 553 534 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b87">Palinski et al 1995</xref>
###xml 555 571 555 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b81">Nagai et al 2002</xref>
###xml 573 593 573 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b110">Sima and Stancu 2002</xref>
###xml 320 325 <span type="species:ncbi:9606">human</span>
###xml 514 520 <span type="species:ncbi:9606">humans</span>
AGEs can form on lipoproteins themselves and AGE-LDL has been shown to have similar atherogenic properties as oxidized LDL (Figure 2). AGE-LDL and AGE-modified protein are ligands for class AI/AII scavenger receptors (Horiuchi et al 2003). Binding to these receptors leads to endocytic uptake of LDL and accumulation in human monocytes-macrophages (Haberland et al 1992; Horiuchi et al 2003). AGE-LDL has been identified in the cytoplasm of foam cells and extracellularly in the core of atherosclerotic lesions in humans and animals (Palinski et al 1995; Nagai et al 2002; Sima and Stancu 2002).
###end p 30
###begin p 31
###xml 657 676 657 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b57">Horiuchi et al 2003</xref>
###xml 781 797 781 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">Brown et al 2005</xref>
HDL's function in reverse cholesterol transport plays a key role in its cardioprotective effect. HDL removes cholesterol from vascular tissue and either transfers it to very low density lipoprotein (VLDL) or LDL for transport to the liver, or it carries cholesterol directly to the liver where it may be recycled or excreted. In dyslipidemia, where HDL is low, cholesterol may be left to accumulate in vascular tissue. It has been suggested that AGEs interfere with reverse cholesterol transport by suppressing scavenger receptor B1 (SR-B1)-mediated uptake of cholesterol ester from HDL by liver and SR-B1-mediated cholesterol efflux from peripheral cells (Horiuchi et al 2003). AGEs have been shown to cause cholesterol and cholesterol ester accumulation in macrophages in vitro (Brown et al 2005).
###end p 31
###begin p 32
###xml 210 224 210 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b117">Suh et al 1992</xref>
###xml 226 245 226 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b71">Mackness et al 2001</xref>
###xml 247 262 247 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b128">Uzun et al 2004</xref>
###xml 264 281 264 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b73">Mancia et al 2005</xref>
###xml 361 390 361 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">Aviram, Rosenblat, et al 1998</xref>
###xml 392 420 392 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">Aviram, Billecke, et al 1998</xref>
###xml 422 436 422 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b93">Rao et al 2003</xref>
###xml 562 576 562 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b93">Rao et al 2003</xref>
###xml 692 720 692 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">Aviram, Billecke, et al 1998</xref>
###xml 770 788 770 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b56">Hedrick et al 2000</xref>
###xml 790 809 790 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">Ferretti et al 2006</xref>
HDL also has antioxidant ability. It is closely associated with the antioxidant enzyme paraoxonase. Low HDL and paraoxonase levels are associated with oxidative stress, hypertension and coronary heart disease (Suh et al 1992; Mackness et al 2001; Uzun et al 2004; Mancia et al 2005). Paraoxonase protects both HDL and LDL from oxidation and lipid peroxidation (Aviram, Rosenblat, et al 1998; Aviram, Billecke, et al 1998; Rao et al 2003). In vitro studies show that paraoxonase lowers levels of oxidized LDL by converting them to biologically inactive products (Rao et al 2003). Blockage of free SH groups (cysteine residues) of paraoxonase reduced its ability to protect LDL from oxidation (Aviram, Billecke, et al 1998) suggesting a possible inhibitory role for AGEs (Hedrick et al 2000; Ferretti et al 2006).
###end p 32
###begin p 33
###xml 194 211 194 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">Barter et al 2004</xref>
###xml 296 314 296 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b56">Hedrick et al 2000</xref>
###xml 316 335 316 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">Ferretti et al 2006</xref>
HDL has also been shown to have antiinflammatory properties. It inhibited cytokine-induced expression of adhesion proteins and reduced neutrophil infiltration into the wall of injured arteries (Barter et al 2004). AGE-modification of HDL resulted in a loss of these anti-inflammatory properties (Hedrick et al 2000; Ferretti et al 2006).
###end p 33
###begin title 34
Low ethanol intake
###end title 34
###begin title 35
Effect on hypertension and atherosclerosis
###end title 35
###begin p 36
###xml 103 118 103 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b125">Thun et al 1997</xref>
###xml 120 139 120 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b96">Reynolds et al 2003</xref>
###xml 141 158 141 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">Corrao et al 2004</xref>
###xml 353 371 353 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">Camargo et al 1997</xref>
###xml 373 391 373 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">Fagrell et al 1999</xref>
###xml 488 495 488 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 861 879 861 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">Ellison et al 2004</xref>
It has been well documented that excessive alcohol intake can be detrimental to cardiovascular health (Thun et al 1997; Reynolds et al 2003; Corrao et al 2004). Although some studies of ethanol intake of greater than 30 g/day have shown improvement in cardiovascular risk, this level of intake increases risk of other diseases and death by other means (Camargo et al 1997; Fagrell et al 1999). Therefore, we have focused our attention in this review on the effects of low ethanol intake (Table 1). Since there is no standard definition of "low" ethanol intake, we have chosen a level of up to, and including, 24 g per day (equivalent to 2 drinks), for the purposes of this discussion. A drink has been defined as a 12 oz bottle or can of beer (4%-5% ethanol), a 4 oz glass of table wine (10%-12% ethanol), or a 1-1.5 oz shot of liquor or spirits (40% ethanol) (Ellison et al 2004).
###end p 36
###begin p 37
Effect of low ethanol on hypertension and atherosclerosis
###end p 37
###begin p 38
Reduced neointimal proliferation, the extent of lipid oxidation and number of foam cells
###end p 38
###begin p 39
Decreased SBP, cytosolic free calcium, tissue AGEs, & renal vascular changes
###end p 39
###begin p 40
U-shaped response of BP to ethanol consumption
###end p 40
###begin p 41
Both light(>0-9 g/day) and moderate (10-34 g/day) ethanol consumption lowered SBP and DBP
###end p 41
###begin p 42
Consumption of 1-2 drinks/day lowered relative risk of all-cause and CV mortality
###end p 42
###begin p 43
###xml 32 35 <span type="species:ncbi:9606">men</span>
30%-40% decrease in CV death in men consuming at least 1 drink/day
###end p 43
###begin p 44
###xml 43 46 <span type="species:ncbi:9606">men</span>
###xml 51 56 <span type="species:ncbi:9606">women</span>
1 drink/day reduced all-cause mortality in men and women
###end p 44
###begin p 45
Consumption of 2-6 drinks/week resulted in a decreased risk in all-cause mortality (mostly a result of a 34%-53% decrease in risk of CV mortality)
###end p 45
###begin p 46
J-shaped response with consumption of both light (0.01-18 g/day) and moderate (18.01-36 g/day) ethanol associated with a decreased risk of IHD
###end p 46
###begin p 47
J-shaped response of BP to ethanol consumption
###end p 47
###begin p 48
Consumption of <18 ml/day of ethanol decreased SBP and DBP
###end p 48
###begin p 49
J-shaped response of ischemic stroke and consumption of <12 g/day of ethanol associated with a reduced risk of total and ischemic stroke
###end p 49
###begin p 50
J-shaped response with BP, cholesterol, and risk of ACS and consumption of <12 g/day associated with a 47% reduction of prevalence of ACS
###end p 50
###begin p 51
J-shaped response with consumption of 20 g/day of ethanol was estimated to provide a 20% reduction in risk of coronary heart disease
###end p 51
###begin p 52
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: ACS, acute coronary syndrome; AGEs, advanced glycation end products; CV, cardiovascular; BP, blood pressure; DBP, dystolic blood pressure; SBP, systolic blood pressure.
###end p 52
###begin p 53
###xml 112 129 112 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b130">Vasdev et al 1999</xref>
###xml 264 282 264 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b59">Jackson et al 1985</xref>
###xml 284 300 284 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b84">Okubo et al 2001</xref>
###xml 650 668 650 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b75">Merritt et al 1997</xref>
###xml 777 795 777 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b65">Klatsky et al 1990</xref>
###xml 797 815 797 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">Camargo et al 1997</xref>
###xml 817 832 817 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b125">Thun et al 1997</xref>
###xml 898 917 898 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b96">Reynolds et al 2003</xref>
###xml 947 965 947 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b51">Genchev et al 2001</xref>
###xml 1091 1110 1091 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b91">Pitsavos et al 2005</xref>
###xml 1231 1248 1231 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">Corrao et al 2004</xref>
###xml 17 20 <span type="species:ncbi:10116">rat</span>
###xml 169 175 <span type="species:ncbi:9606">humans</span>
###xml 499 505 <span type="species:ncbi:9986">rabbit</span>
###xml 674 680 <span type="species:ncbi:9606">humans</span>
###xml 980 988 <span type="species:ncbi:9606">patients</span>
We have shown in rat models of hypertension that chronic low ethanol is effective in decreasing blood pressure (Vasdev et al 1999). Two studies of low ethanol intake in humans, one using up to 9 g/day and the other up to 18 g/day, showed antihypertensive effects (Jackson et al 1985; Okubo et al 2001). Most animal research that looked specifically at atherosclerotic vascular changes, used moderate to high levels of ethanol. However, one study which fed low ethanol to an atherosclerotic model of rabbit showed that it attenuated atherosclerosis with a decrease in the extent of neointimal proliferation, lipid oxidation, and number of foam cells (Merritt et al 1997). In humans, low ethanol consumption reduced risk for both cardiovascular and non-cardiovascular mortality (Klatsky et al 1990; Camargo et al 1997; Thun et al 1997) and was associated with a significantly reduced risk of stroke (Reynolds et al 2003) and ischemic heart disease (Genchev et al 2001). In diabetic patients, low ethanol intake was associated with a 47% reduction in the prevalence of acute coronary syndrome (Pitsavos et al 2005) and in individuals known to be at risk for cardiovascular disease, a 20% reduction in risk of coronary artery disease (Corrao et al 2004).
###end p 53
###begin title 54
Mechanism of beneficial effect
###end title 54
###begin p 55
###xml 93 100 93 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 432 440 432 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3</xref>
###xml 631 632 631 632 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 942 953 942 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b69">Lieber 1990</xref>
###xml 1496 1497 1496 1497 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 1617 1628 1617 1628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b69">Lieber 1990</xref>
###xml 1630 1646 1630 1646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">Bello et al 1994</xref>
###xml 1908 1916 1908 1916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4</xref>
###xml 1089 1092 <span type="species:ncbi:10116">rat</span>
Low ethanol has been shown to improve the clinical manifestations of cardiovascular disease (Table 1), but what is the biochemical mechanism of this beneficial effect? We suggest that low ethanol intake has the ability to increase antioxidant capacity, improve insulin resistance and decrease AGEs, thus preventing subsequent hypertensive and atherosclerotic consequences. To begin, we need to understand the metabolism of ethanol (Figure 3). Ethanol is metabolized differently at high and low concentrations. With chronic high ethanol intake, the microsomal ethanol oxidizing system (MEOS) is induced. MEOS has a relatively high Km for ethanol, and at high concentrations ethanol is metabolized to acetaldehyde without producing reduced nicotinamide adenine dinucleotide (NADH). Instead, this pathway utilizes reduced nicotinamide adenine dinucleotide phosphate (NADPH), another reducing equivalent, thus producing an oxidative environment (Lieber 1990). Additionally, chronic high ethanol consumption inhibits aldehyde dehydrogenase resulting in a significant decrease in the ability of rat mitochondria to oxidize acetaldehyde. This high ethanol intake thus associated with an enhanced rate of metabolism by the MEOS pathway resulting in a decrease in reducing equivalents, elevated acetaldehyde, and increased oxidative stress. These factors may account for the detrimental effects of high ethanol intake. However, at low ethanol blood levels, ethanol is metabolized very efficiently by low Km alcohol dehydrogenase to acetaldehyde and then by aldehyde dehydrogenase to acetate, producing NADH in both reactions (Lieber 1990; Bello et al 1994). NADH has a major influence on total antioxidant capacity of the body. NADH is a key component of the electron transport chain and, due to its high reducing potential functions to promote regeneration of endogenous vitamin radicals back to their reduced form (Figure 4). Although ethanol is primarily metabolized in the liver, it is also metabolized in other tissues, including vascular tissue. This ability of ethanol at low concentrations to create a strong reducing environment, possibly at the site of atherosclerotic activity, may enhance its cardiovascular protective effect.
###end p 55
###begin p 56
###xml 314 315 314 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 559 560 559 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Metabolism of high versus low concentrations of ethanol. In high concentrations, ethanol is metabolized by the microsomal ethanol oxidizing system (MEOS) system. In this reaction, reduced nicotinamide adenine dinucleotide phosphate (NADPH) is converted to oxidized nicotinamide adenine dinucleotide phosphate (NADP+) creating an oxidative environment. In low concentrations, ethanol is metabolized by the enzymes alcohol and aldehyde dehydrogenase producing reduced nicotinamide adenine dinucleotide (NADH) from oxidized nicotinamide adenine dinucleotide (NAD+) by both reactions, increasing antioxidant capacity. At the low levels produced, acetate, which is a normal metabolite of glucose and fatty acid metabolism, is further metabolized in the citric acid cycle.
###end p 56
###begin p 57
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 265 266 265 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 311 312 311 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Antioxidant activity of low ethanol. Free radicals (ROO-) are reduced (ROOH) by vitamins which become oxidized in the process. These vitamin radicals are reduced by nicotinamide adenine dinucleotide (NADH) which forms oxidized nicotinamide adenine dinucleotide (NAD+). Ethanol in low concentrations converts NAD+ back into NADH, via its metabolism to acetate. At this low level, acetate, which is a normal metabolite of glucose and fatty acid metabolism, is further metabolized in the citric acid cycle.
###end p 57
###begin p 58
###xml 85 94 85 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figures 4</xref>
###xml 99 100 99 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">5</xref>
###xml 168 184 168 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">Bello et al 1994</xref>
###xml 350 380 350 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">Bonnefont-Rousselot et al 2001</xref>
###xml 471 489 471 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b147">Yoshida et al 2001</xref>
###xml 579 598 579 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">Bushehri et al 1998</xref>
###xml 776 788 776 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b97">Rodwell 1983</xref>
###xml 1024 1047 1024 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b103">Schauenstein et al 1977</xref>
###xml 1049 1066 1049 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b129">Vasdev et al 1998</xref>
###xml 386 392 <span type="species:ncbi:9606">humans</span>
An increase in antioxidant capacity would offer protection against oxidative stress (Figures 4 and 5) and secondary production of aldehydes through lipid peroxidation (Bello et al 1994). In vitro, ethanol has been shown to act as an antioxidant by decreasing the rate of consumption of LDL antioxidants and reducing the formation of lipid peroxides (Bonnefont-Rousselot et al 2001). In humans, it decreased urinary 8-hydroxydeoxyguanosine, a measure of oxidative stress (Yoshida et al 2001). NADH treatment has been shown to reduce blood pressure and lipid peroxidation in SHRs (Bushehri et al 1998). NADH may also increase overall antioxidant capacity, increasing tissue levels of cysteine by converting cystine to cysteine, via the NADH dependent enzyme, cystine reductase (Rodwell 1983). Cysteine is a precursor of glutathione, a major endogenous antioxidant. Additionally, glutathione is a cofactor in methylglyoxal catabolism and cysteine has the ability to bind aldehydes to foster excretion and reduce AGE formation (Schauenstein et al 1977; Vasdev et al 1998).
###end p 58
###begin p 59
Mechanism of action of low ethanol.
###end p 59
###begin p 60
###xml 173 195 173 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b102">Scharfstein et al 1994</xref>
###xml 322 339 322 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b135">Venkov et al 1999</xref>
###xml 463 482 463 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b66">Kuhlmann et al 2004</xref>
###xml 621 644 621 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b137">Vlachopoulos et al 2003</xref>
###xml 862 879 862 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b130">Vasdev et al 1999</xref>
###xml 964 990 964 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b77">Mitidieri and de Meis 1995</xref>
###xml 1171 1179 1171 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5</xref>
###xml 485 491 <span type="species:ncbi:9606">Humans</span>
###xml 758 761 <span type="species:ncbi:10116">rat</span>
An increase in the low molecular weight thiols, cysteine and glutathione, may also enhance the transfer of NO from protein-bound reserves improving endothelial dysfunction (Scharfstein et al 1994). Decreasing levels of AGEs may also preserve eNOS and prevent breakdown of NO. Low ethanol increased the expression of eNOS (Venkov et al 1999) and stimulated calcium-activated potassium channels increasing production of NO in vascular endothelial cells in culture (Kuhlmann et al 2004). Humans consuming low amounts of ethanol showed significant dilatation of brachial artery at rest and at reactive hyperaemic conditions (Vlachopoulos et al 2003). Low ethanol decreases cytosolic free calcium, an initiator of smooth muscle cell contraction. We have shown in rat models of essential hypertension that low ethanol reduced AGEs and platelet cytosolic free calcium (Vasdev et al 1999). Low ethanol activated sarco/endoplasmic reticulum uptake of calcium in platelets (Mitidieri and de Meis 1995) which would lower cytosolic free calcium concentration. This effect of ethanol on vascular dilation/contraction regulators may contribute to its beneficial cardiovascular effect (Figure 5).
###end p 60
###begin p 61
###xml 60 79 60 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">Facchini et al 1994</xref>
###xml 81 100 81 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47">Flanagan et al 2000</xref>
###xml 115 132 115 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b50">Furuya et al 2003</xref>
###xml 296 304 296 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5</xref>
###xml 371 388 371 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b80">Morgan et al 2002</xref>
###xml 390 412 390 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">Beisswenger et al 2003</xref>
###xml 659 677 659 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">Avogaro et al 2002</xref>
###xml 52 58 <span type="species:ncbi:9606">humans</span>
###xml 109 113 <span type="species:ncbi:10116">rats</span>
Low alcohol intake increased insulin sensitivity in humans (Facchini et al 1994; Flanagan et al 2000) and in rats (Furuya et al 2003). Improving insulin resistance, the source of excess aldehydes, would limit formation of AGES and their subsequent hypertensive and atherosclerotic complications (Figure 5). Since aldehydes and AGEs have also been shown to inhibit GAPDH (Morgan et al 2002; Beisswenger et al 2003), likely further exacerbating insulin resistance, reducing AGE formation may limit the effect of this cycle. Low ethanol may also work to improve insulin resistance by lowering plasma free fatty acids and improving glucose uptake and metabolism (Avogaro et al 2002).
###end p 61
###begin p 62
###xml 68 76 68 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5</xref>
###xml 123 142 123 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">Facchini et al 1994</xref>
###xml 144 174 144 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">De Oliviera e Silva et al 2000</xref>
###xml 176 194 176 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">Ellison et al 2004</xref>
###xml 424 441 424 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">Catena et al 2003</xref>
###xml 559 589 559 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">De Oliviera e Silva et al 2000</xref>
###xml 693 714 693 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b54">Hannuksela et al 1996</xref>
###xml 835 849 835 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b93">Rao et al 2003</xref>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
###xml 818 822 <span type="species:ncbi:10116">rats</span>
###xml 827 833 <span type="species:ncbi:9606">humans</span>
Low ethanol intake has a beneficial effect on lipoprotein profiles (Figure 5). Low ethanol has been shown to increase HDL (Facchini et al 1994; De Oliviera e Silva et al 2000; Ellison et al 2004). This increase may be a result of mediating the AGE-induced inhibitory effect on reverse cholesterol transport. In hypertensive patients low ethanol decreased lipoprotein a (Lp[a]), an independent predictor for atherosclerosis (Catena et al 2003). It has been suggested that this may be due to an increase in the transportation rate of apolipoprotein AI and AII (De Oliviera e Silva et al 2000) or to an ethanol-induced redistribution of cholesteryl ester transport proteins between HDL and VLDL (Hannuksela et al 1996). Chronic low ethanol intake stimulated paraoxonase activity by upregulating liver paraoxonase mRNA in rats and humans (Rao et al 2003). Ethanol may also prevent inhibition of paraoxonase by lowering AGEs.
###end p 62
###begin title 63
Implication for treatment
###end title 63
###begin p 64
###xml 656 672 656 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">Duffy et al 1999</xref>
###xml 674 690 674 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b111">Singh et al 1999</xref>
###xml 692 710 692 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b131">Vasdev et al 2000a</xref>
###xml 712 717 712 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b132">2000b</xref>
###xml 719 723 719 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b134">2002</xref>
###xml 725 742 725 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b79">Morcos et al 2001</xref>
###xml 744 762 744 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">Barrios et al 2002</xref>
###xml 764 782 764 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">Boshtam et al 2002</xref>
###xml 894 913 894 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b113">Stampfer et al 1993</xref>
###xml 915 934 915 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b70">Losonczy et al 1996</xref>
###xml 936 955 936 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b114">Stephens et al 1996</xref>
###xml 1184 1204 1184 1204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64">Kislinger et al 2001</xref>
###xml 1206 1227 1206 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">Degenhardt et al 2002</xref>
###xml 1229 1248 1229 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b78">Mizutani et al 2002</xref>
###xml 1250 1269 1250 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">Alderson et al 2003</xref>
###xml 1271 1295 1271 1295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">Babaei-Jadidi et al 2003</xref>
###xml 1297 1315 1297 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b76">Midaoui et al 2003</xref>
###xml 1317 1337 1317 1337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b101">Sakaguchi et al 2003</xref>
###xml 1339 1360 1339 1360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b112">Smit and Lutgers 2004</xref>
###xml 1362 1378 1362 1378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b115">Stitt et al 2004</xref>
###xml 620 626 <span type="species:ncbi:9606">humans</span>
###xml 788 794 <span type="species:ncbi:9606">humans</span>
We have suggested that low ethanol intake affords beneficial cardiovascular effects due to its ability to improve insulin resistance and its subsequent detrimental effects. However, due to the addictive nature of alcohol, recommending ethanol intake at any level may not be prudent. It may be more appropriate to suggest other agents which act in a similar fashion and may provide the same beneficial effects without the complication of addiction. Supplementation with antioxidants including vitamin C, E, or B6, N-acetylcysteine, lipoic acid and coenzyme Q10 has been shown to lower blood pressure in animal models and humans with essential hypertension (Duffy et al 1999; Singh et al 1999; Vasdev et al 2000a, 2000b, 2002; Morcos et al 2001; Barrios et al 2002; Boshtam et al 2002). In humans, antioxidants have also shown a beneficial effect on atherosclerotic endpoints in several studies (Stampfer et al 1993; Losonczy et al 1996; Stephens et al 1996). As well, various anti-AGE therapies, which either prevent or reverse AGE formation, such as pyridoxamine, thiamine, metformin, alagebrium, or soluble RAGE have been shown to attenuate hypertension and atherosclerotic disease (Kislinger et al 2001; Degenhardt et al 2002; Mizutani et al 2002; Alderson et al 2003; Babaei-Jadidi et al 2003; Midaoui et al 2003; Sakaguchi et al 2003; Smit and Lutgers 2004; Stitt et al 2004).
###end p 64
###begin title 65
Conclusion
###end title 65
###begin p 66
In summary, insulin resistance leads to altered glucose and lipid metabolism. A subsequent increase in AGEs, oxidative stress, and endothelial dysfunction leads to the development of hypertension and atherosclerosis. Low ethanol intake provides cardiovascular beneficial effect primarily through its ability to increase antioxidant capacity, improving insulin resistance and decreasing AGEs. Considering the potential for addiction with ethanol consumption, agents such as antioxidants which have similar antihypertensive and anti-atherosclerotic mechanisms, may provide an appropriate alternative.
###end p 66
###begin p 67
We would like to thank the Canadian Institutes of Health Research for their financial support.
###end p 67
###begin title 68
References
###end title 68
###begin article-title 69
###xml 110 114 <span type="species:ncbi:10116">rats</span>
The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats
###end article-title 69
###begin article-title 70
Role of s-nitosation of cysteine residues in long-lasting inhibitory effect of nitric oxide on arterial tone
###end article-title 70
###begin article-title 71
Insulin stimulates glyceraldehyde-3-phosphate dehydrogenase gene expression through CIS-acting DNA sequences
###end article-title 71
###begin article-title 72
Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease
###end article-title 72
###begin article-title 73
Chemical modification of muscle protein in diabetes
###end article-title 73
###begin article-title 74
###xml 58 65 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#603;</sup>
###xml 30 35 <span type="species:ncbi:9606">human</span>
The myeloperoxidase system in human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation
###end article-title 74
###begin article-title 75
Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes
###end article-title 75
###begin article-title 76
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its function
###end article-title 76
###begin article-title 77
###xml 206 211 <span type="species:ncbi:9606">human</span>
Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities. Selective action of human paraoxonase allozymes Q nd R
###end article-title 77
###begin article-title 78
Glucose tolerance during moderate alcohol intake: Insights on insulin action from glucose/lactate dynamics
###end article-title 78
###begin article-title 79
Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine
###end article-title 79
###begin article-title 80
###xml 91 99 <span type="species:ncbi:9606">patients</span>
N-Acetylcysteine potentiates the antihypertensive effect of ACE inhibitors in hypertensive patients
###end article-title 80
###begin article-title 81
Antiinflammatory properties of HDL
###end article-title 81
###begin article-title 82
Glycoxidation and lipoxidation in atherogenesis
###end article-title 82
###begin article-title 83
Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly
###end article-title 83
###begin article-title 84
Glyceraldehyde-3-phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes
###end article-title 84
###begin article-title 85
###xml 50 55 <span type="species:ncbi:9606">human</span>
Cardioprotective effects of alcohol: mediation by human vascular alcohol dehydrogenase
###end article-title 85
###begin article-title 86
Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids
###end article-title 86
###begin article-title 87
Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium-release channels
###end article-title 87
###begin article-title 88
###xml 62 67 <span type="species:ncbi:9606">human</span>
Antioxidant effect of ethanol toward in vitro peroxidation of human low-density lipoproteins initiated by oxygen free radicals
###end article-title 88
###begin article-title 89
Vitamin E can reduce blood pressure in mild hypertensives
###end article-title 89
###begin article-title 90
Interaction of DNA with bifunctional aldehydes
###end article-title 90
###begin article-title 91
Glycation of low-density lipoproteins by methylglyoxal and glycoaldehyde gives rise to the in vitro formation of lipid-laden cells
###end article-title 91
###begin article-title 92
###xml 134 138 <span type="species:ncbi:10116">rats</span>
###xml 140 143 <span type="species:ncbi:10116">SHR</span>
Oral reduced B-nicotinamide adenine dinucleotide (NADH) affects blood pressure, lipid peroxidation, and lipid profile in hypertensive rats (SHR)
###end article-title 92
###begin article-title 93
Prospective study of moderate alcohol consumption and mortality in US male physicians
###end article-title 93
###begin article-title 94
Serum lipoprotein(a) concentrations and alcohol consumption in hypertension: possible relevance for cardiovascular damage
###end article-title 94
###begin article-title 95
Atherosclerosis: Its pathophysiology with special reference to lipid peroxidation
###end article-title 95
###begin article-title 96
Substrate-induced up-regulation of aldose reductase by methylglyoxal, a reactive oxoaldehyde elevated in diabetes
###end article-title 96
###begin article-title 97
Methylglyoxal-induced nitric oxide and peroxynitrite production in vascular smooth muscle cells
###end article-title 97
###begin article-title 98
Cysteine 184 of endothelial nitric oxide synthase is involved in heme coordination and catalytic activity
###end article-title 98
###begin article-title 99
Exacerbation of atherosclerosis by hypertension
###end article-title 99
###begin article-title 100
###xml 71 76 <span type="species:ncbi:9606">women</span>
The receptor for advanced glycation end products (RAGE) is elevated in women with preeclampsia
###end article-title 100
###begin article-title 101
A meta-analysis of alcohol consumption and the risk of 15 diseases
###end article-title 101
###begin article-title 102
Lipid peroxidation - a common pathogenetic mechanism?
###end article-title 102
###begin article-title 103
Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension and atherosclerotic cardiovascular disease
###end article-title 103
###begin article-title 104
###xml 86 89 <span type="species:ncbi:10116">rat</span>
Pyridoxamine inhibits early renal disease and dyslipidemia in streptozotocin-diabetic rat
###end article-title 104
###begin article-title 105
Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II
###end article-title 105
###begin article-title 106
Thrombogenic and lipid risk factors in hypertension and coronary artery disease
###end article-title 106
###begin article-title 107
Treatment of hypertension with ascorbic acid
###end article-title 107
###begin article-title 108
Lifestyle determinants of high-density lipoprotein cholesterol: The National Heart, Lung, and Blood Institute Family Heart Study
###end article-title 108
###begin article-title 109
Light-to-moderate alcohol intake is associated with enhanced insulin sensitivity
###end article-title 109
###begin article-title 110
The effects of light to moderate drinking on cardiovascular diseases
###end article-title 110
###begin article-title 111
Proteins lose their nitric oxide stabilizing function after advanced glycosylation
###end article-title 111
###begin article-title 112
Structural modifications of HDL and functional consequences
###end article-title 112
###begin article-title 113
Insulin resistance in essential hypertension
###end article-title 113
###begin article-title 114
Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia
###end article-title 114
###begin article-title 115
Alcohol consumption and insulin resistance in young adults
###end article-title 115
###begin article-title 116
Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias
###end article-title 116
###begin article-title 117
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Abnormalities of carbohydrate and lipid metabolism in patients with hypertension
###end article-title 117
###begin article-title 118
###xml 57 68 <span type="species:ncbi:10116">Wistar rats</span>
Low ethanol consumption increases insulin sensitivity in Wistar rats
###end article-title 118
###begin article-title 119
Does alcohol protect against ischemic heart disease in Bulgaria? A case-control study of non-fatal myocardial infarction in Sofia
###end article-title 119
###begin article-title 120
###xml 71 76 <span type="species:ncbi:9606">human</span>
Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages
###end article-title 120
###begin article-title 121
###xml 25 30 <span type="species:ncbi:9606">human</span>
Increased aggregation of human platelets produced by advanced glycation end products in vitro
###end article-title 121
###begin article-title 122
Ethanol-induced redistribution of cholesteryl ester transfer protein (CEPT) between lipoproteins
###end article-title 122
###begin article-title 123
Inflammation, atherosclerosis, and coronary artery disease
###end article-title 123
###begin article-title 124
Glycation impairs high-density lipoprotein function
###end article-title 124
###begin article-title 125
Scavenger receptors for oxidized and glycated proteins
###end article-title 125
###begin article-title 126
Insulin sensitivity and atherosclerosis
###end article-title 126
###begin article-title 127
Alcohol consumption and blood pressure
###end article-title 127
###begin article-title 128
Nitric oxide: The "second messenger" of insulin
###end article-title 128
###begin article-title 129
###xml 147 151 <span type="species:ncbi:10116">rats</span>
Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats
###end article-title 129
###begin article-title 130
Free radicals and the heart
###end article-title 130
###begin article-title 131
###xml 63 68 <span type="species:ncbi:9606">human</span>
Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins
###end article-title 131
###begin article-title 132
###xml 157 161 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice
###end article-title 132
###begin article-title 133
Risk of cardiovascular mortality in alcohol drinkers, ex-drinkers and nondrinkers
###end article-title 133
###begin article-title 134
###xml 31 33 31 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 45 46 45 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Dose-dependent activation of Ca2+-activated K+ channels by ethanol contributes to improved endothelial cell functions
###end article-title 134
###begin article-title 135
###xml 50 55 <span type="species:ncbi:9606">human</span>
Are free radicals involved in the pathobiology of human essential hypertension?
###end article-title 135
###begin article-title 136
Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia
###end article-title 136
###begin article-title 137
Mechanism of ethanol induced hepatic injury
###end article-title 137
###begin article-title 138
###xml 107 114 <span type="species:ncbi:9606">persons</span>
Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly
###end article-title 138
###begin article-title 139
Paraoxonase status in coronary heart disease. Are activity and concentration more important than genotype?
###end article-title 139
###begin article-title 140
Low-density lipoprotein oxidation in essential hypertension
###end article-title 140
###begin article-title 141
Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population
###end article-title 141
###begin article-title 142
Carbohydrate metabolism
###end article-title 142
###begin article-title 143
###xml 78 84 <span type="species:ncbi:9986">rabbit</span>
Moderate alcohol feeding attenuates postinjury vascular cell proliferation in rabbit angioplasty model
###end article-title 143
###begin article-title 144
Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production
###end article-title 144
###begin article-title 145
Ethanol has different effects on Ca (2+)-transport ATPases of muscle, brain and blood platelets
###end article-title 145
###begin article-title 146
###xml 125 129 <span type="species:ncbi:10116">rats</span>
Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats
###end article-title 146
###begin article-title 147
###xml 93 101 <span type="species:ncbi:9606">patients</span>
Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study
###end article-title 147
###begin article-title 148
Inactivation of cellular enzymes by carbonyls and protein-bound glycation/glycoxidation products
###end article-title 148
###begin article-title 149
###xml 18 23 <span type="species:ncbi:9606">human</span>
Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycoaldehyde-modified proteins
###end article-title 149
###begin article-title 150
###xml 85 89 <span type="species:ncbi:10116">rats</span>
Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal
###end article-title 150
###begin article-title 151
Why lowering blood pressure is not enough: the hypertension syndrome and the clinical context of cardiovascular risk reduction
###end article-title 151
###begin article-title 152
Alcohol consumption and blood pressure change: 5 year follow-up study of the association in normotensive workers
###end article-title 152
###begin article-title 153
Systemic and cellular calcium metabolism and hypertension
###end article-title 153
###begin article-title 154
Methylglyoxal modification of protein
###end article-title 154
###begin article-title 155
###xml 120 127 <span type="species:ncbi:9986">rabbits</span>
Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits
###end article-title 155
###begin article-title 156
Identification of the binding site of methylglyoxal on glutathione peroxidase: Methylglyoxal inhibits glutathione peroxidase activity via binding to glutathione binding sites Arg 184 and 185
###end article-title 156
###begin article-title 157
The vascular biology of hypertension and atherosclerosis and intervention with calcium antagonists and angiotensin-converting enzyme inhibitors
###end article-title 157
###begin article-title 158
The cardiovascular effects of alcohol: the good and the bad. How low-risk drinking differs from high-risk drinking
###end article-title 158
###begin article-title 159
The J-shape effect of alcohol intake on the risk of developing acute coronary syndromes in diabetic subjects: the CARDIO 2000 II Study
###end article-title 159
###begin article-title 160
Oxidative stress in essential hypertension
###end article-title 160
###begin article-title 161
###xml 92 96 <span type="species:ncbi:10116">rats</span>
###xml 101 107 <span type="species:ncbi:9606">humans</span>
Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans
###end article-title 161
###begin article-title 162
Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease
###end article-title 162
###begin article-title 163
Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders. The mechanism of "syndrome X"
###end article-title 163
###begin article-title 164
Alcohol consumption and risk of stroke
###end article-title 164
###begin article-title 165
Catabolism of the carbon skeletons of amino acids
###end article-title 165
###begin article-title 166
Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products
###end article-title 166
###begin article-title 167
Atherosclerosis - An inflammatory disease
###end article-title 167
###begin article-title 168
Insulin resistance and hypertension. The insulin resistance atherosclerosis study
###end article-title 168
###begin article-title 169
Central role of RAGE-dependent neointimal expansion in arterial restenosis
###end article-title 169
###begin article-title 170
In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols
###end article-title 170
###begin article-title 171
Aldehydes in biological systems
###end article-title 171
###begin article-title 172
The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses
###end article-title 172
###begin article-title 173
###xml 63 65 60 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">II</sub>
AGEs induce oxidative stress and activate protein kinase C-betaII in neonatal mesangial cells
###end article-title 173
###begin article-title 174
###xml 65 69 <span type="species:ncbi:10116">rats</span>
Abnormalities of insulin receptors in spontaneously hypertensive rats
###end article-title 174
###begin article-title 175
Immunological evidence for methylglyoxal-derived modifications in vivo
###end article-title 175
###begin article-title 176
Molecular mechanism of impaired endothelial function associated with insulin resistance
###end article-title 176
###begin article-title 177
Demonstration of insulin resistance in coronary artery disease documented with angiography
###end article-title 177
###begin article-title 178
###xml 36 41 <span type="species:ncbi:9606">human</span>
Modified lipoproteins accumulate in human coronary atheroma
###end article-title 178
###begin article-title 179
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease
###end article-title 179
###begin article-title 180
The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation
###end article-title 180
###begin article-title 181
###xml 58 63 <span type="species:ncbi:9606">women</span>
Vitamin E consumption and the risk of coronary disease in women
###end article-title 181
###begin article-title 182
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)
###end article-title 182
###begin article-title 183
Advanced glycation and advanced lipoxidation: possible role in initiation and progression of diabetic retinopathy
###end article-title 183
###begin article-title 184
Role of oxidative modifications in atherosclerosis
###end article-title 184
###begin article-title 185
Alcohol use and mortality from coronary heart disease: The role of high-density lipoprotein cholesterol
###end article-title 185
###begin article-title 186
Mechanisms of endothelial dysfunction: Clinical significance and preventative non-pharmacological therapeutic strategies
###end article-title 186
###begin article-title 187
TAGE (toxic AGEs) hypothesis in various diseases
###end article-title 187
###begin article-title 188
The genesis of atherosclerosis and risk factors: A review
###end article-title 188
###begin article-title 189
The autoxidation of glyceraldehyde and other simple monosaccharides under physiological conditions catalysed by buffer ions
###end article-title 189
###begin article-title 190
Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry
###end article-title 190
###begin article-title 191
The glyoxalase system in health and disease
###end article-title 191
###begin article-title 192
Maillard reaction products in tissue proteins: New products and new perspectives
###end article-title 192
###begin article-title 193
Alcohol consumption and mortality among middle-aged and elderly U.S. adults
###end article-title 193
###begin article-title 194
Reactive oxygen species in vascular biology: implications for hypertension
###end article-title 194
###begin article-title 195
###xml 45 50 <span type="species:ncbi:9606">human</span>
Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3', 5'-cyclic monophosphate and adenosine-3', 5'-cyclic monophosphate
###end article-title 195
###begin article-title 196
Oxidative stress in white coat hypertension; role of paraoxonase
###end article-title 196
###begin article-title 197
###xml 33 37 <span type="species:ncbi:10116">rats</span>
Aldehyde induced hypertension in rats: Prevention by N-acetylcysteine
###end article-title 197
###begin article-title 198
###xml 76 80 <span type="species:ncbi:10116">rats</span>
Antihypertensive effect of low ethanol intake in spontaneously hypertensive rats
###end article-title 198
###begin article-title 199
###xml 94 98 <span type="species:ncbi:10116">rats</span>
Dietary alpha-lipoic acid supplementation lowers blood pressure in spontaneously hypertensive rats
###end article-title 199
###begin article-title 200
###xml 78 82 <span type="species:ncbi:10116">rats</span>
Dietary lipoic acid supplementation prevents fructose-induced hypertension in rats
###end article-title 200
###begin article-title 201
Role of methylglyoxal in essential hypertension
###end article-title 201
###begin article-title 202
Nutrition and hypertension
###end article-title 202
###begin article-title 203
Ethanol increases endothelial nitric oxide production through modulation of nitric oxide synthase expression
###end article-title 203
###begin article-title 204
###xml 102 108 <span type="species:ncbi:9986">rabbit</span>
Inhibition of nitric oxide synthase activity by early and advanced glycation end products in cultured rabbit proximal tubular epithelial cells
###end article-title 204
###begin article-title 205
Effect of alcohol on endothelial function in health subjects
###end article-title 205
###begin article-title 206
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Insulin secretion, sensitivity, and metabolic profile of young healthy offspring of hypertensive patients
###end article-title 206
###begin article-title 207
###xml 102 106 <span type="species:ncbi:10116">rats</span>
Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats
###end article-title 207
###begin article-title 208
###xml 23 31 <span type="species:ncbi:9606">patients</span>
Cardiovascular risk in patients with end-stage renal disease: a potential role for advanced glycation end products
###end article-title 208
###begin article-title 209
Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE
###end article-title 209
###begin article-title 210
Role of oxidized low density lipoprotein in atherogenesis
###end article-title 210
###begin article-title 211
Advanced glycation end products stimulate an enhanced neutrophil respiratory burst mediated through the activation of cytosolic phospholipase A2 and generation of arachidonic acid
###end article-title 211
###begin article-title 212
World Health Report. Chapter 6: Neglected global epidemics: three growing threats [online]
###end article-title 212
###begin article-title 213
Global strategy on diet, physical activity and health: chronic disease risk factors
###end article-title 213
###begin article-title 214
###xml 61 64 <span type="species:ncbi:10116">rat</span>
Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells
###end article-title 214
###begin article-title 215
Moderate alcohol consumption reduces urinary 8-hydroxydeoxyguanosine by inducing of uric acid
###end article-title 215
###begin article-title 216
###xml 30 32 30 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Reactive disulfides trigger Ca2+ release from sarcoplasmic reticulum via an oxidation reaction
###end article-title 216

